Therapixel

Nice, France All France companies → — Founded 2013

Imaging AI Specialist Specialty-Focused AI

Radiology

Oncology AI Radiology & Imaging AI

Series B — $22.1M

Claim this company

Products

MammoScreen

Therapixel

Oncology AI

MammoScreen is an FDA-cleared AI software by Therapixel that assists radiologists in breast cancer screening by detecting and characterizing suspicious lesions in 2D and 3D mammograms, providing a MammoScreen Score™ to indicate malignancy likelihood, and improving diagnostic accuracy and efficiency.

Subscription (saas model)

See all 1 product →

About Therapixel

Therapixel is a leading French software company specializing in artificial intelligence (AI) solutions for medical imaging, with a primary focus on breast cancer screening. Their flagship product, MammoScreen®, is an AI-based software designed to assist radiologists in the interpretation of screening mammograms, including both 2D and 3D (tomosynthesis) images. MammoScreen® is FDA-cleared and CE-marked, demonstrating its compliance with stringent regulatory standards in key healthcare markets.

The software leverages deep learning algorithms, trained on extensive datasets of mammograms annotated by breast radiology experts, to efficiently and accurately detect and characterize suspicious breast cancer lesions. It provides a unique “MammoScreen Score™” to indicate the level of suspicion, enabling radiologists to quickly confirm certain lesions and prioritize cases requiring closer attention, thereby enhancing diagnostic accuracy and reducing interpretation time for benign cases.

Beyond lesion detection, recent advancements in MammoScreen® integrate AI across various aspects of the breast imaging workflow. These new features include worklist management with a complexity index to reduce radiologist fatigue, case pre-check for patient health history, breast density assessment, and pre-reporting to automatically generate screening evaluation reports. By streamlining these processes and offering a comprehensive suite of tools, Therapixel aims to improve workflow efficiency, support earlier cancer detection, and ultimately contribute to better patient outcomes in breast cancer screening programs globally.

Focus Areas

Artificial Intelligence Medical Imaging Breast Cancer Screening Mammography (2D/3D) Deep Learning Computer Vision Radiology Workflow Optimization Breast Density Assessment

Business Intelligence

Key Investors	Crédit Mutuel Innovation, CapHorn Invest, Verve Ventures, Sham Innovation Santé, Omnes, IT-Translation (now Elaia), M-Capital Partners, Région Sud Investissement, MedTech Accelerator
Partnerships	RamSoft (May 2025), ONsite Women's Health (April 2025), Mayo Clinic (June 2025), Milvue (September 2023), Qure.ai (February 2023)
Acquisitions	Sold its surgical products unit Therapixel Suite to Videomed in June 2020
Technology	Cloud-native (via RamSoft OmegaAI integration), Deep Learning, Neural Networks, Applied Mathematics, Computer Vision, AI-powered software
FDA Clearances	3 cleared products (estimated)

What Physicians Need to Know

Artificial Intelligence & Deep Learning

Therapixel specializes in applying advanced AI, deep learning, and computer vision to medical imaging. Their flagship product, MammoScreen, utilizes neural networks trained on hundreds of thousands of expert-annotated mammograms to precisely analyze high-resolution images (4000 x 3000 pixels) for breast lesions, including subtle masses and microcalcifications.

Breast Cancer Screening & Mammography (2D/3D)

Their core expertise lies in enhancing breast cancer screening through AI-powered interpretation of both 2D and 3D mammograms. MammoScreen is FDA-cleared and CE-marked, providing comprehensive analysis for detecting and characterizing suspicious lesions.

Radiology Workflow Optimization

MammoScreen is designed to streamline the entire radiology workflow. It includes features like intelligent worklist management with a complexity index, case pre-check for patient history, efficient screening assessment by incorporating prior exams, automated breast density assessment, and pre-reporting to populate structured results.

Breast Density Assessment

A key feature of the latest MammoScreen version is its ability to provide automated breast density assessment, assisting radiologists with this critical reporting requirement.

Physician Tip

For physicians, Therapixel's MammoScreen acts as an intelligent co-pilot, significantly improving diagnostic accuracy by detecting subtle and early-stage cancers, including microcalcifications, that might otherwise be overlooked. It dramatically enhances efficiency by reducing reading and reporting times (up to 24% faster, 35% quicker interpretation, 17% faster turnaround) and mitigating radiologist fatigue (up to 40% reduction). The actionable MammoScreen Scoreu2122 and integration of prior exams boost diagnostic confidence and reduce unnecessary patient recalls, minimizing anxiety. Its seamless integration into existing PACS workflows means no disruption, allowing radiologists to focus on critical cases and deliver faster, more confident results to women.

Therapixel's MammoScreen is designed for seamless integration into existing radiology ecosystems. It has established partnerships and integrations with leading platforms such as RamSoft (PowerServer and OmegaAI), Arterys, Nuance Precision Imaging Network, and Onsite Women's Health. Additionally, Therapixel collaborates with companies like CureMetrix to offer integrated solutions (e.g., with cmAngio for breast arterial calcification detection) for a more holistic approach to women's health.

At a glance

Founded 2013

HQ Nice, France · France

Team size approximately 49-57

CEO Matthieu Leclerc-Chalvet

Funding Series B — $22.1M

FDA clearances 3 (estimated)

Products 1

Products by Therapixel

1 product in the directory

MammoScreen

Therapixel

Oncology AI

Subscription (saas model)

Reviews & Opinions

No web reviews on file yet for Therapixel. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Therapixel.

Loading videos...

Videos load interactively. If none appear, search YouTube for Therapixel →

View all on YouTube

Press & Coverage

Therapixel Blog

MammoScreenu00ae Breast AI Adopted by Mayo Clinic for Radiology Use

Mayo Clinic has adopted Therapixel's MammoScreenu00ae Breast AI for radiology use, indicating a significant integration of AI in breast cancer screening at a major medical institution.

2025-06

PR Newswire

Therapixel and Onsite Women's Health Announce Partnership to Deploy MammoScreenu00ae AI for Enhanced Breast Cancer Detection Across National Provider Network

Therapixel has partnered with Onsite Women's Health to deploy MammoScreenu00ae AI across over 150 locations, aiming to enhance breast cancer detection and improve patient outcomes.

2025-04

Healthcare IT Today

Therapixel's AI-Based Breast Cancer Detection Technology Now Integrated with RamSoft

Therapixel's AI-based breast cancer detection technology, MammoScreen, has been integrated into RamSoft's cloud-based PACS platform to improve detection and efficiency in radiology.

2025-06

PR Newswire

Therapixel Announces Two New FDA Clearances for its Most Advanced Breast Cancer Screening AI Solution

Therapixel received two new FDA 510(k) clearances for MammoScreen, enhancing its AI solution for breast cancer screening with features like priors, case pre-check, and pre-reporting.

2024-10

Axis Imaging News

Therapixel Secures Two New FDA Clearances for Breast Cancer AI

Therapixel's updated MammoScreen, with new FDA clearances, integrates AI features beyond lesion detection to streamline the breast imaging process, reducing radiologist fatigue and reading time.

2024-10

Applied Radiation Oncology

CureMetrix and Therapixel Collaborate to Expand Access to Breast AI Imaging Solutions

CureMetrix and Therapixel have partnered to integrate cmAngiou00ae with MammoScreenu00ae, expanding access to advanced breast imaging AI tools and offering a more holistic approach to women's health.

2025-11

Therapixel

Therapixel announces close of 15 Mu20ac series B financing to deploy MammoScreenu00ae 2D/3D

Therapixel closed a u20ac15 million Series B financing round, led by Crédit Mutuel Innovation and CapHorn, to accelerate the commercial deployment of MammoScreenu00ae 2D/3D in the United States.

2022-05

PubMed (Radiology: Artificial Intelligence)

Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool

A study published in Radiology: Artificial Intelligence demonstrated that the concurrent use of Therapixel's AI tool improved radiologists' diagnostic performance in breast cancer detection without prolonging their workflow.

2020-11

Frequently Asked Questions

What is Therapixel's core product and how does its AI technology enhance breast cancer screening?

Therapixel's flagship product is MammoScreenu00ae, an FDA-cleared and CE-marked AI software designed to assist radiologists in interpreting 2D and 3D mammograms for breast cancer screening. It utilizes deep learning algorithms, trained on extensive datasets, to detect and characterize suspicious lesions and calcifications, and can leverage prior exams to improve accuracy.

How does MammoScreenu00ae optimize radiology workflow and address concerns like breast density assessment?

MammoScreenu00ae optimizes workflow through features like case pre-check, pre-reporting, and worklist management with a complexity index, aiming to reduce radiologist fatigue and save time. It also includes an FDA-cleared breast density assessment feature, helping radiologists accurately categorize breast tissue composition.

What are Therapixel's compliance and regulatory certifications for its AI solutions?

Therapixel is ISO/IEC 27001 certified for information security management and ISO 13485 compliant, demonstrating a commitment to data security and quality management. Its MammoScreenu00ae product holds both FDA clearance in the United States and CE marking in Europe, affirming its clinical safety and reliability.

What is Therapixel's pricing model and how can healthcare providers obtain support?

MammoScreenu00ae is offered through a Software as a Service (SaaS) model, where customers pay based on the volume of mammograms successfully processed, ensuring access to the latest software versions without additional charges. While specific pricing details are not publicly disclosed, interested healthcare providers can contact Therapixel directly for personalized quotes and product demonstrations, with support teams available in their offices in Paris, Nice, and Chicago.

What strategic partnerships has Therapixel established within the healthcare industry?

Therapixel has formed strategic partnerships to expand the reach and capabilities of MammoScreenu00ae, including collaborations with CureMetrix for integrated breast cancer and cardiovascular risk assessment, RamSoft for seamless integration into RIS/PACS platforms, and Onsite Women's Health for deployment across a national provider network. Additionally, Mayo Clinic has adopted MammoScreen, and Therapixel connects to the Nuance Precision Imaging Network to enhance collaborative care.

What is the company's financial stability and history?

Founded in 2013, Therapixel has demonstrated financial stability, having raised over u20ac20 million in funding, including a significant u20ac15 million Series B round in May 2022. Key investors include Crédit Mutuel Innovation, CapHorn, Omnes, IT-Translation, M-Capital, and Région Sud Investissement, supporting the company's commercial expansion, particularly in the United States.

Related Companies

Suggest an Edit →